CYP19A1 and breast cancer: This updated analysis of the phase 2 FAKTION trial after 5 years of follow-up showed that the addition of capivasertib to fulvestrant resulted in a clinically and statistically significant prolongation of overall survival in participants with aromatase inhibitor-resistant ER-positive, HER2negative advanced breast cancer.